Home › Funds › Lion Point Capital, LP › EWTX
Lion Point Capital, LP position in EWTX
EDGEWISE THERAPEUTICS INC · Health Care
Lion Point Capital, LP reported holding 9,100 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$370K, representing 1.77% of its reported portfolio and ranking #22 among its reported holdings. Lion Point Capital, LP has disclosed EWTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Lion Point Capital, LP's EWTX position evolved
Lion Point Capital, LP first disclosed a stake in EWTX in Q4 2025 at 9,100 shares (US$226K). The position peaked in Q2 2026 at 9,100 shares, worth US$370K. Across 3 filings, Lion Point Capital, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 9,100 shares valued at US$370K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 9.10K | $225.82K | New |
| Q1 2026 | 9.10K | $286.65K | Hold |
| Q2 2026 | 9.10K | $369.73K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EWTX and 13F data
EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in EWTX — the largest reported positions include ORBIMED ADVISORS LLC (US$630.5M), Paradigm Biocapital Advisors LP (US$415.1M), RA CAPITAL MANAGEMENT, L.P. (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EWTX
- ORBIMED ADVISORS LLC 15.52M sh · $630.52M · Q2 2026
- Paradigm Biocapital Advisors LP 10.22M sh · $415.05M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 8.39M sh · $341.00M · Q2 2026
- Novo Holdings A/S 5.35M sh · $217.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.73M sh · $192.12M · Q2 2026
- PERCEPTIVE ADVISORS LLC 4.37M sh · $177.71M · Q2 2026
- BAKER BROS. ADVISORS LP 3.70M sh · $150.40M · Q2 2026
- Siren, L.L.C. 3.18M sh · $129.39M · Q2 2026
- Cormorant Asset Management, LP 2.51M sh · $101.98M · Q2 2026
- Integral Health Asset Management, LLC 2.00M sh · $81.26M · Q2 2026
- BRAIDWELL LP 2.00M sh · $81.14M · Q2 2026
- MPM BioImpact LLC 1.62M sh · $65.85M · Q2 2026
More on Lion Point Capital, LP
FAQ
How long has Lion Point Capital, LP held EWTX?
Lion Point Capital, LP has disclosed EWTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Lion Point Capital, LP's current position in EWTX?
As of Q2 2026, Lion Point Capital, LP holds 9.10K shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $369.73K, representing 1.77% of its reported portfolio and ranking #22.
Has Lion Point Capital, LP been buying or selling EWTX?
In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in EWTX. The position peaked in Q2 2026 at 9.10K shares.
Which other funds hold EWTX?
Other major institutional holders of EWTX include ORBIMED ADVISORS LLC, Paradigm Biocapital Advisors LP, RA CAPITAL MANAGEMENT, L.P., among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.